| Impacts of sodium/glucose cotransporter-2 inhibitors on circulating uric acid concentrations: a systematic review and meta-analysis. | 2022 | Journal of Diabetes Research |
| Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis. | 2022 | Canadian Journal of Diabetes |
| Comparative cardiovascular outcomes of SGLT2 inhibitors in type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials. | 2022 | Frontiers in Endocrinology |
| Comparative efficacy of five SGLT2i on cardiorenal events: a network meta-analysis based on ten CVOTS. | 2022 | American Journal of Cardiovascular Drugs |
| Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials. | 2022 | Journal of Cardiovascular Pharmacology |
| Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials. | 2022 | European Heart Journal- Quality of Care and Clinical Outcomes |
| Beneficial effect of sodium-glucose co-transporter 2 inhibitors on left ventricular function. | 2022 | The Journal of Clinical Endocrinology & Metabolism |
| Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. | 2022 | European Journal of Preventative Cardiology |
| Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. | 2022 | Frontiers in Endocrinology |
| Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: a network meta-analysis based on randomized controlled trials. | 2022 | Journal of Clinical Pharmacy and Therapeutics |
| Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. | 2021 | Heart Failure Reviews |
| High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials. | 2021 | Diabetes, Obesity and Metabolism |
| Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: a systematic review and meta-analysis. | 2021 | IJC Heart and Vasculature |
| The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: a systematic review and meta-analysis. | 2021 | Diabetes, Obesity and Metabolism |
| Do SGLT2 inhibitors improve cardio-renal outcomes in patients with type II diabetes mellitus: a systematic review. | 2021 | Cureus |
| Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. | 2021 | Heart Rhythm |
| Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients. | 2021 | Medicine |
| Microvascular benefits of new antidiabetic agents: a systematic review and network meta-analysis of kidney outcomes. | 2021 | Journal of Clinical Endocrinology & Metabolism |
| Empagliflozin in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. | 2021 | Frontiers in Cardiovascular Medicine |
| Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. | 2021 | Diabetes Research and Clinical Practice |
| Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. | 2021 | Cardiovascular Drugs and Therapy |
| Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. | 2021 | Diabetes, Obesity and Metabolism |
| Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. | 2020 | Annals of Internal Medicine |
| SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. | 2020 | The Lancet Diabetes and Endocrinology |
| Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. | 2020 | The Lancet Diabetes and Endocrinology |
| Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis. | 2020 | PLoS One |
| Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: a systematic review and meta-analysis. | 2020 | Medical Sciences |
| Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: a systematic review and meta-analysis. | 2020 | Medicine |
| Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis. | 2019 | PLoS Medicine |
| Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized controlled trials. | 2019 | Diabetes Research and Clinical Practice |
| Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: systematic literature review and indirect comparisons. | 2018 | Diabetes Therapy |
| Efficacy and safety of empagliflozin for type 2 diabetes mellitus: meta-analysis of randomized controlled trials. | 2018 | Medicine |
| SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: a systematic review and meta-analysis. | 2018 | Diabetes Obesity and Metabolism |
| Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: a systematic review with an indirect comparison meta-analysis. | 2018 | Saudi Journal of Biological Sciences |
| Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials. | 2018 | CMAJ Open |
| Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. | 2018 | Diabetes and Metabolism |
| SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. | 2017 | Diabetologia |
| Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus. | 2017 | Diabetes Research and Clinical Practice |
| Sodium–glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. | 2017 | Diabetes Obesity and Metabolism |
